Selpercatinib for the treatment of patients with advanced RET fusion positive non-small-cell lung cancer

19 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...

Read more →

Durvalumab in combination with etoposide phosphate and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small-cell lung cancer

19 February 2025 - NICE has published final evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin ...

Read more →

Unravelling the association between uncertainties in model-based economic analysis and funding recommendations of medicines in Australia

14 February 2025 - Health technology assessment is used extensively by the PBAC to inform medicine funding recommendations in Australia.  ...

Read more →

Keytruda gets expanded coverage for 11 indications at cancer disease panel

13 February 2025 - After nearly two years of stalled discussions, the Keytruda (pembrolizumab) reimbursement expansion debate has finally begun. ...

Read more →

Olaparib for the treatment of patients with advanced, BRCA mutation positive, HER2 negative breast cancer after chemotherapy

12 February 2025 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) for the treatment of ...

Read more →

NICE joins international collaboration on HTA methods research

12 February 2025 - We’ve partnered with the US based ICER and the Canadian Drug Agency (CDA-AMC) to establish the Health ...

Read more →

Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration untreated with a targeted cancer medicine

12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...

Read more →

Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration after treatment with a targeted cancer medicine (final guidance)

12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...

Read more →

Ganaxolone for the treatment of patients 2 years of age and older with seizures caused by CDKL5 deficiency disorder

12 February 2025 - NICE has published final evidence-based recommendations on the use of ganaxolone (Ztalmy) for the treatment of ...

Read more →

Gilead’s breast cancer treatment Trodelvy passes drug reimbursement panel

7 February 2025 - Gilead's triple negative breast cancer treatment Trodelvy (trastuzumab govitecan) had surmounted a significant hurdle for health ...

Read more →

Nivolumab and ipilimumab for the first-line treatment of patients with metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

10 February 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

ICER releases draft evidence report on treatment for advanced retinitis pigmentosa

6 February 2025 - Public comment period now open until 6 March 2025; requests to make oral comment during public ...

Read more →

ICER publishes evidence report on treatment for acute pain

5 February 2025 - Current evidence suggests that suzetrigine may provide a net health benefit when compared to no systemic ...

Read more →

February 2025 decisions

10 February 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

Update on regulatory review of lecanemab for early Alzheimer’s disease in the European Union (July 2024)

26 July 2024 - Eisai and Biogen announced today that the CHMP of the EMA has adopted a negative opinion on ...

Read more →